PharmaMar will present in the ESMO congress results of lurbinectedin on Ovarian Cancer

On August 10, 2018 PharmaMar (MSE:PHM) has reported that it has been notified by ESMO (Free ESMO Whitepaper) (European Society for Medical Oncology) that its abstract titled "Phase III trial of Lurbinectedin versus PLD or Topotecan in platinum-resistant ovarian cancer patients: Results of CORAIL trial" has been accepted as an oral presentation which will take place October 19th at 1415 CET at the 2018 Congress in Munich, Germany

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!